Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-11-30FDA Approved: LAMOTRIGINE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for a generic lamotrigine product.
-
CLINICAL_TRIALS trial_result · 2018-11-27Clinical Trial Update: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU [Phase 3]
Phase 3 study evaluating USL261 for epilepsy has completed with posted results.
-
FDA approval · 2018-11-20FDA Approved: VIGABATRIN — Original Application (Dr. Reddys Laboratories Inc.,)
FDA approved the original abbreviated new drug application for Vigabatrin (generic) manufactured by Dr. Reddys Laboratories Inc.
-
EMA withdrawal · 2018-11-19EMA Withdrawn: Trobalt (retigabine) — Glaxo Group Limited
The EMA has withdrawn Trobalt (retigabine) from the market.
-
FDA approval · 2018-11-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., signaling an update to its labeling and indication.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-11-11FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., updating the labeling for this antiepileptic drug.
-
CLINICAL_TRIALS trial_result · 2018-10-26Clinical Trial Update: Premenstrual Dysphoric Disorder and Antiepileptic Drugs
Clinical trial update related to premenstrual dysphoric disorder and antiepileptic drugs; results completed with results posted.
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved an original ANDA for CLOBAZAM from Amneal Pharmaceuticals NY LLC, authorizing the generic version of clobazam.
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved the original application for CLOBAZAM (clobazam) from Upsher-Smith Laboratories, LLC, as a generic anticonvulsant product. The …
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Amneal Pharmaceuticals NY LLC)
The FDA approved Amneal Pharmaceuticals' original ANDA for CLOBAZAM (clobazam), enabling the generic version of the epilepsy medication to b…
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Taro Pharmaceuticals U.S.A., Inc.)
FDA approved CLOBAZAM (clobazam) through an Original Abbreviated New Drug Application for Taro Pharmaceuticals U.S.A., Inc., representing a …
-
FDA approval · 2018-10-22FDA Approved: CLOBAZAM — Original Application (Bionpharma Inc.)
FDA approves CLOBAZAM as a generic clobazam product via an Original Application (ANDA) for Bionpharma Inc.; submission status is AP.
-
FDA approval · 2018-10-18FDA Approved: DILANTIN-125 — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN-125 (phenytoin) submitted by Viatris Specialty LLC. This action approves an update to a…
-
FDA approval · 2018-10-18FDA Approved: ACETAZOLAMIDE — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s Original Application for acetazolamide, confirming a generic version of the drug. The approval allows …
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures [Phase 3]
Phase 3 trial update on eslicarbazepine acetate as monotherapy for newly diagnosed partial-onset seizures.
-
CLINICAL_TRIALS trial_result · 2018-10-16Clinical Trial Update: Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) [Phase 2]
Phase 2 trial comparing diazepam nasal spray to diazepam rectal gel (Diastat) for bioavailability, safety, and tolerability in refractory ep…
-
FDA approval · 2018-10-16FDA Approved: GABAPENTIN — Original Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved the original generic application for gabapentin, enabling a generic version of the anticonvulsant for the same indications as t…
-
CLINICAL_TRIALS trial_result · 2018-10-11Clinical Trial Update: Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus [Phase 3]
Phase 3 trial comparing lorazepam, clonazepam, and clonazepam plus fosphenytoin for out-of-hospital generalized status epilepticus has compl…
-
CLINICAL_TRIALS trial_result · 2018-10-01Clinical Trial Update: Monotherapy With Levetiracetam in Patients Suffering From Epilepsy. [Phase 3]
A Phase 3 monotherapy trial of levetiracetam in epilepsy patients has completed, with results posted in 2018.
-
FDA approval · 2018-09-27FDA Approved: FYCOMPA — Supplemental Application (Eisai Inc.)
The FDA approved a supplemental application for FYCOMPA (perampanel) submitted by Eisai Inc. The approval updates the drug’s labeling/indica…
-
FDA approval · 2018-09-19FDA Approved: CERETEC — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approved a supplemental application for CERETEC (technetium-99m exametazime), a radiopharmaceutical imaging agent, to modify/expand its …
-
CLINICAL_TRIALS trial_result · 2018-09-13Clinical Trial Update: Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility [Phase 1, Phase 2]
Clinical trial update on transcutaneous vagal nerve stimulation assessing miRNA, inflammation, cerebral resting state, and gastric motility …
-
FDA label_change · 2018-09-12FDA Approved: LEVETIRACETAM — Supplemental Application (Prasco Laboratories)
The FDA granted a supplemental labeling/approval for LEVETIRACETAM through Prasco Laboratories under NDA 207958.
-
CLINICAL_TRIALS trial_result · 2018-09-11Clinical Trial Update: An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol [Phase 2]
An open-label Phase 2 extension study evaluated possible drug-drug interactions between clobazam and cannabidiol in epilepsy patients; compl…
-
CLINICAL_TRIALS trial_result · 2018-08-29Clinical Trial Update: A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs) [Phase 2]
Long-term extension study of E2007 in patients with refractory partial seizures completed; results posted in 2018.